James L. Khatcheressian

Hematology | Hematology Oncology

8007 Discovery Drive
Suite A
Richmond, VA 23229

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 6 publications

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Journal: JAMA

Published: December 29, 2016

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

Journal: The oncologist

Published: July 05, 2016

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 25, 2016

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 15, 2015

Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.

Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 07, 2012

Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Journal: Clinical genitourinary cancer

Published: October 25, 2012

Showing 1-6 of 6

Last Updated: 09/26/2026